"Empirical Antibiotics for Sepsis Linked to Acute Kidney Injury"

A randomized clinical trial compared the use of piperacillin-tazobactam and cefepime for empirical treatment of sepsis and found no significant difference in the risk of acute kidney injury (AKI) between the two antibiotics. The trial also showed that patients treated with cefepime had fewer days alive and free of delirium and coma compared to those treated with piperacillin-tazobactam. The study provides evidence that piperacillin-tazobactam does not increase the risk of AKI compared to cefepime, but cefepime may be associated with a higher risk of neurological dysfunction.